LCM
IMVT icon

Legato Capital Management’s Immunovant IMVT Stock Holding History

Legato Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,840
Closed -$383K – 596
2024
Q1 		$383K Hold
11,840
– – 0.05% 480
2023
Q4 		$499K Buy
11,840
+5,061
+75% +$186K 0.07% 417
2023
Q3 		$260K Buy
+6,779
New +$153K 0.04% 492

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Legato Capital Management's IMVT Position: Q2 2024 in Review

Legato Capital Management sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 11,840 shares — an estimated $383K sold.

Legato Capital Management first reported a position in IMVT in Q3 2023 and held it in 3 quarters. The position peaked at $499K in Q4 2023. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Legato Capital Management reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Legato Capital Management sold 11,840 Immunovant shares in Q2 2024, an estimated $383K.
  • Legato Capital Management first reported a position in Immunovant in Q3 2023 and held it in 3 quarters.
  • Legato Capital Management's Immunovant position peaked at $499K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Legato Capital Management's 13F filing for Q2 2024, filed 26 Jul 2024.